Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Pharmacoeconomics|December 16, 2010
Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisalMatt Stevenson, Abdullah Pandor
Health Technology Assessment (Winchester, England)|March 25, 2021
Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysisMatt Stevenson, Andrew Metry, Michael Messenger
Health Economics|December 19, 2006
Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVAAnthony O'Hagan, Matt Stevenson, Jason Madan
Current Rheumatology Reports|September 4, 2014
Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic reviewJonathan Tosh, Matt Stevenson, Ron Akehurst
Health Technology Assessment (Winchester, England)|June 18, 2021
Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysisMatt Stevenson, Andrew Metry, Michael Messenger
Pharmacoeconomics|October 13, 2012
Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisalSophie Whyte, Abdullah Pandor, Matt Stevenson
Journal of the Intensive Care Society|October 6, 2017
Benchmarking rehabilitation practice in the intensive care unitAnna Knott, Matt Stevenson, Stephanie Km Harlow
Pharmacoeconomics|October 5, 2013
Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisalLesley Uttley, Ben Kearns, Shijie Ren, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 3, 2009
A rapid-response economic evaluation of the UK NHS Cancer Reform Strategy breast cancer screening program extension via a plausible bounds approachJason Madan, Andrew Rawdin, Matt Stevenson, et al.
Vaccine|March 22, 2002
Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination scheduleMatt Stevenson, Stephen Beard, Adam Finn, et al.
Pageof 7